5 Key Takeaways
-
1
Nearly 10 million patients with diabetes in the U.S. have diabetic retinopathy, with 5% experiencing vision-threatening disease.
-
2
Dulaglutide and semaglutide are strongly associated with worsening diabetic retinopathy, while liraglutide and tirzepatide show a weaker link.
-
3
GLP-1 agonists improve glycemic control, which may temporarily worsen diabetic retinopathy, necessitating further research.
-
4
Optometrists should maintain close communication with primary care physicians regarding GLP-1 agonist prescriptions for patients with existing diabetic retinopathy.
-
5
Assistive technologies like OCT-A and fundus photography are recommended for monitoring diabetic retinopathy in patients using GLP-1 agonists.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.